Comments
Cadila Healthcare has said in a statement that the Mexican regulatory authority COFEPRIS has granted marketing approval to commercialise Lipaglyn (Saroglitazar magnesium) in Mexico. The drug is used to treat dyslipidemia in patients with diabetes mellitus type 2 and hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins. Zydus is also evaluating Saroglitazar to treat liver conditions.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.